Satoru Yamakawa

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Efficacy of Esaxerenone Plus a Renin-Angiotensin System Inhibitor or Calcium Channel Blocker for Nocturnal Hypertension: A Post Hoc Analysis.

Efficacy of Esaxerenone Plus a Renin-Angiotensin System Inhibitor or Calcium Channel Blocker for Nocturnal Hypertension: A Post Hoc Analysis.

Journal: American journal of hypertension

Published: September 04, 2024

Antihypertensive Effect of Long-Term Monotherapy with Esaxerenone in Patients with Essential Hypertension: Relationship Between Baseline Urinary Sodium Excretion and Its Antihypertensive Effect.

Antihypertensive Effect of Long-Term Monotherapy with Esaxerenone in Patients with Essential Hypertension: Relationship Between Baseline Urinary Sodium Excretion and Its Antihypertensive Effect.

Journal: Advances in therapy

Published: April 27, 2022

Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes.

Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension

Published: August 31, 2021

Pharmacological profile, clinical efficacy, and safety of esaxerenone (Minnebro® tablets 1.25 mg, 2.5 mg, 5 mg)

Pharmacological profile, clinical efficacy, and safety of esaxerenone (Minnebro® tablets 1.25 mg, 2.5 mg, 5 mg)

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica

Published: September 04, 2020

Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone.

Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension

Published: August 11, 2020

Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study.

Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study.

Journal: American journal of hypertension

Published: June 16, 2020

Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study).

Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study).

Journal: Hypertension (Dallas, Tex. : 1979)

Published: December 03, 2019

Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension.

Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension

Published: April 09, 2019

Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study.

Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study.

Journal: Journal of human hypertension

Published: December 18, 2018

Showing 1-9 of 9

Last Updated: 09/26/2026